Lisavanbulin

Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008) . Lisavanbulin is a BBB-penetrant and orally active antitumor agent, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin is also a spindle assembly checkpoint activator. Lisavanbulin induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma[1][2][3][4].

Product Specifications

CAS Number

[1263384-43-5]

Product Name Alternative

BAL-101553

UNSPSC

12352005

Target

Checkpoint Kinase (Chk) ; Microtubule/Tubulin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lisavanbulin.html

Purity

99.24

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(C(CN2C3=CC=CC=C3N=C2C4=NON=C4NCCC#N)=O)C=C1)[C@@H](N)CCCCN

Molecular Formula

C26H29N9O3

Molecular Weight

515.57

References & Citations

[1]Spriano F, et al. Assessment of lisavanbulin (BAL101553) as an anti-lymphoma agent[J]. bioRxiv, 2023: 2022.12. 31.521730.|[2]Joerger, M., et al., (2023) . Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Investigational new drugs, 41 (2), 267–275. |[3]Holdhoff, M., et al., (2024) . Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma. Neuro-oncology advances, 6 (1), vdae150. |[4]Genoud, V., et al., (2021) . Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin) . JCI insight, 6 (18), e142980.